Intellipharmaceutics International Inc.
DelistedCIK 1474835fmd_0464BHVX9M9H94EAJS20F891JVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Dec 01, 2009 to Aug 31, 2023, 38 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 2 | 9 | 4 | 6 | 2 | 3 | 1 | 0 | 0 |
| Cost of revenue | – | – | – | – | 1 | 0 | 0 | 0 | 0 | – |
| Gross profit | – | – | – | – | 5 | 2 | 3 | 1 | 0 | – |
| Research and development | 6 | 5 | 8 | 7 | 9 | 11 | 7 | 4 | 3 | 2 |
| Selling, general and administrative | 4 | 3 | 4 | 4 | 3 | 3 | 4 | 2 | 1 | 1 |
| Total operating expenses | – | – | – | – | – | – | 11 | 6 | 4 | 3 |
| Operating income | – | – | – | – | (8) | (13) | (8) | (5) | (4) | (3) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Income before taxes | – | – | – | – | (9) | (14) | (8) | (3) | (5) | (3) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 3 | (5) | – |
| Net income from continuing operations | (10) | (7) | (4) | (7) | (9) | (14) | (16) | (7) | (0) | – |
| Net income | (6) | (11) | (4) | (7) | (9) | (14) | (8) | (3) | (5) | (3) |